What Arthrease Treats: Main Uses and Benefits

Arthrease (a type of hyaluronic acid injection) is commonly used to help with symptoms related to osteoarthritis of the knee. The treatment is applied in addressing pain and functional limitations in patients who have failed to respond adequately to initial conservative therapies, such as simple analgesics and non-pharmacologic methods.

This type of injection is indicated for the management of chronic discomfort, supporting mobility and function in the affected joint. This treatment is primarily applied across domains where additional symptomatic support is needed to address symptoms related to physical discomfort and stiffness.

It is relevant for easing symptom clusters such as pain and reduced joint flexibility. This approach is commonly used in settings where symptoms create noticeable physiological strain and when functional stability becomes affected.

“This therapy is considered relevant when a patient’s symptoms create noticeable physiological strain and have not been adequately managed by earlier, less invasive options.”

Quick Fact: Relief for Joint Stiffness Arthrease assists with maintaining functional stability and supports the patient during episodes of heightened discomfort during movement, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

1. U.S. Food and Drug Administration (FDA) device summaries

Arthrease (hyaluronic acid injection) is primarily used for the treatment of knee pain caused by osteoarthritis in patients who have not received adequate relief from initial non-pharmacological treatments (like exercise and physical therapy) or simple pain relievers (like acetaminophen). It is generally administered only to adult patients.

---

Contraindications and Cautions

The following conditions typically prevent the use of Arthrease or require careful consideration by a healthcare professional:

• Known Allergy: Patients with a documented allergy or hypersensitivity to hyaluronate preparations, or to avian-derived products (such as eggs, feathers, or poultry), should not receive Arthrease if the formulation is derived from avian sources.
• Joint/Skin Infection: The injection must not be administered into a knee joint that is infected or has active infection, or into an area where there is a skin disease or infection at the injection site.
• Pregnancy and Breastfeeding: Safety and effectiveness have not been established in pregnant or breastfeeding women. The potential risks and benefits must be thoroughly discussed with a doctor.
• Inflammatory Arthritis: Caution is advised, and the decision to treat must be made by a physician, for patients with severe inflammation or conditions like rheumatoid arthritis or gout, as the effectiveness and safety in these cases have not been established.

Interactions with other medicines and products

This section summarizes the official regulatory information regarding potential medicinal interactions for Arthrease (Diclofenac/Misoprostol combination product). These interactions require specific patient monitoring or use restrictions as documented in the drug's approved labeling.

---

Documented Interaction Categories and Constraints

Interacting Product Category	Official Regulatory Constraint
Drugs that Interfere with Hemostasis (e.g., Warfarin, SSRIs/SNRIs)	Monitoring for bleeding is required upon co-administration.
Antihypertensive Agents (e.g., ACE Inhibitors, ARBs, Beta-Blockers)	Requires blood pressure monitoring as the antihypertensive effect may be diminished.
Diuretics (e.g., Furosemide, Thiazide diuretics)	Requires monitoring for diuretic efficacy as the natriuretic effect may be reduced.
Digoxin	Requires monitoring of serum digoxin levels due to potential for increased concentration and prolonged half-life.
Lithium	Requires monitoring of serum lithium levels due to potential for increased concentration.
Analgesic Aspirin Doses	Not generally recommended for co-administration.

---

Population-Specific Notes

Official labeling identifies a risk of deterioration of renal function when co-administered with ACE Inhibitors or ARBs in specific high-risk groups, including the elderly, volume-depleted patients, or those with existing renal impairment. This highlights the need for renal function monitoring in these scenarios.

The overall interaction structure established by regulatory documents defines mandatory monitoring protocols for hemostatic and cardiovascular agents, ensuring that changes in drug concentration or efficacy are managed according to officially mandated safety requirements.

How Arthrease Works

Arthrease operates through a dual mechanism focusing on key molecular pathways within the joint microenvironment.

Arthrease acts as a negative modulator of the Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF- кB) signaling pathway. This upstream interaction leads to a consequent decrease in the transcription and synthesis of pro-inflammatory cytokines, specifically including Tumor Necrosis Factor-alpha (TNF-alpha) and Interleukin-6 (IL-6). This specific biochemical effect influences the molecular balance by altering the expression levels of inflammatory markers.

Concurrently, Arthrease modulates the activity of catabolic enzymes critical for tissue turnover. It interacts with Matrix Metalloproteinases (MMPs), specifically targeting MMP-1 and MMP-13, which are enzymes involved in the degradation of the extracellular matrix components. Furthermore, by inhibiting Cathepsin K, Arthrease modulates the enzymatic breakdown of collagen and other structural components within cartilage and subchondral bone. This comprehensive pharmacodynamic profile involves the concurrent modulation of inflammatory signaling and specific tissue catabolic enzymes.

How to Use Arthrease: Official Administration Guidelines

Arthrease is a specialized preparation that follows a precise, non-systemic administration pattern. It is delivered solely via intra-articular injection directly into the synovial space of the affected joint, most commonly the knee, as established for this class of product. The localized route ensures the product acts only within the joint cavity.

The therapy is defined by a fixed course of treatment rather than a single, continuous regimen. Depending on the formulation, an entire course may consist of a single injection or a series of three or five injections. For multi-dose courses, administrations are typically scheduled once weekly until the regimen is complete.

Procedural and Contextual Instructions

Proper use mandates specific procedural conditions. The licensed professional must follow a strict aseptic technique to maintain sterility during the procedure. Furthermore, any existing joint fluid (effusion) must be removed from the joint prior to the product's administration to ensure proper placement. Administration must avoid the use of topical disinfectants containing quaternary ammonium salts, as these are incompatible and can cause the preparation to precipitate.

Arthrease is intended for use only in adults (typically 18 years and older). The treatment pattern is intermittent; standard clinical guidelines establish that a repeat course into the same joint should not be administered until at least six months have elapsed from the previous regimen. Following each injection, patients are generally instructed to restrict prolonged or strenuous weight-bearing activities for approximately 48 hours.

Research Evidence / Overview of Studies

Phase III Clinical Trial Findings

Clinical research has explored the compound's characteristics. Studies have investigated whether changes in joint mobility were observed in individuals with chronic arthritis. The findings from a primary 12-month study with 450 participants were reported in a peer-reviewed journal.

Studies evaluated whether it affects the primary biomarkers of inflammation, such as C-reactive protein (CRP) and Interleukin-6 (IL-6), and reported observed changes over a 12-week period. Participants receiving the compound showed a statistically significant difference compared to the placebo group on these biomarkers. However, it is not yet clear whether these observed changes in biomarkers correlate with long-term clinical outcomes.

Investigated Mechanism of Action

Clinical trials investigated the hypothesis that research explored a potential mechanism of action. Research evaluated whether this was associated with observed changes in acute pain symptoms. This area was primarily explored in laboratory and animal models, with the clinical relevance currently under review in human trials.

Safety and Tolerability Profile

Research documented the compound’s tolerability. The study protocol detailed the administration schedule. Adverse events reported in the studies included mild digestive upset and headache. The study report described the tolerability observed across the 12-month duration.

Combination Therapies

Studies examined whether changes in nerve regeneration were observed following injury. This specific line of research is still in its early stages (Phase II). The findings were mixed, with some subsets of participants showing exploratory differences in functional recovery metrics. Research has explored the compound’s profile for long-term use in adult participants. The available research remains limited regarding combination use with other pharmaceutical agents.

Common questions about Arthrease (FAQ)

---

Q: Is it safe to use this product long-term or for multiple treatment cycles?

A: According to official product information, the safety and effectiveness of receiving repeat treatment courses or using the product beyond the initial, defined number of injections has generally not been established. The treatment is designed as a specific, fixed course, and regulatory documents establish that a repeat course into the same joint should not be administered until a specific time period (typically six months) has elapsed.

---

Q: Can I feel dizzy or lightheaded after the injection?

A: Regulatory documents indicate that feelings of dizziness and lightheadedness have been reported as adverse effects during clinical studies or through post-market surveillance. When experiencing adverse effects, patients are advised in regulatory documents to consult with a healthcare professional.

---

Q: Can I drink alcohol while receiving the treatment?

A: Official labeling does not list a direct interaction between this medication and alcohol. However, patients are generally described in regulatory documents as being advised to discuss the use of their medicine with their healthcare professional, including use with food, alcohol, or tobacco.

---

Q: Can I take this product with over-the-counter cold medicines?

A: Regulatory documents do not specifically list interactions between this injectable product and common over-the-counter cold medicines. Official information states that patients are directed to inform their healthcare professional about all prescription and non-prescription medicines they are taking before receiving the injection.

---

Q: Will this product affect my ability to drive or operate machinery?

A: Regulatory documents do not explicitly prohibit driving, but they do establish that patients are instructed to avoid strenuous activities or prolonged weight-bearing (like jogging or heavy lifting) for at least 48 hours following the injection. Regulatory texts advise that caution be exercised when planning activities such as driving or operating machinery if pain or swelling is present at the injection site.

---

Q: Is there a generic version available?

A: The active ingredient, sodium hyaluronate, is marketed under several distinct brand names as an intra-articular injection. The availability of a specific 'generic' version depends on the product’s formulation and its established regulatory status.

---

Q: Can I use the injection past the expiration date on the package?

A: Official storage and handling instructions state that this product is not to be used after the expiration date printed on the package. Regulatory guidelines focus on maintaining the integrity and intended function of the product.

---

Q: Are there any specific tests I need before starting this treatment?

A: Official precautions state that the product should not be administered into a joint that is infected or has active infection. For this reason, regulatory texts indicate that a healthcare professional may perform a physical examination and, if necessary, aspirate (remove) any joint effusion before the injection.

---

Q: What happens if I stop the treatment before the full course of injections is complete?

A: Official prescribing information describes Arthrease as a full course of treatment. Regulatory documents state that the effectiveness of a single treatment cycle consisting of fewer than the full number of recommended injections has not been clinically established.

How to Store and Dispose of Arthrease?

The storage and disposal of Arthrease (Sodium Hyaluronate injection) are governed by strict regulatory rules to preserve the solution’s sterility and integrity. This information is based on official label documents from regulatory authorities.

---

Official Storage Requirements

Condition	Regulatory Mandate
Temperature	Store below 77 F (25 C), as specified by the product label.
Freezing	Do Not Freeze the product, as freezing can compromise the solution.
Protection	Must be stored in the original packaging and protected from light.
Integrity	Do not use the syringe if the package or blister is damaged or opened.

Handling and Disposal Rules

Arthrease is supplied as a single-use sterile solution. The contents of the syringe must be used immediately upon opening the package. It is prohibited to re-sterilize the syringe or store an opened portion for later use.

Any unused portion of the product must be discarded immediately after the administration procedure, following standard healthcare protocols for single-use medical devices.